Paula Olaizola Rebé. Gaixotasun Hepatikoak Taldea, Biodonostia OII.

Jesús María Bañales Dk., eta María Jesús Perugorria Dk.




Cholangiocarcinoma (CCA) comprises a heterogeneous group of malignant tumors with dismal prognosis. Surgical resection and liver transplantation remain the only curative treatments, since conventional chemotherapy is mostly palliative. Therefore, unveiling the mechanisms driving its development and progression are crucial to find new therapeutic targets for clinical intervention. This project arises from the idea that not everything that determines the tumor development and subsequent behaviour, as their response to antitumor drugs, is “written” in the genes, but there is a complex cellular machinery that regulates the functionality of proteins and that certain elements of gear can be altered in situations where the initiation of liver cancer is favored, such as cirrhosis. This project aims to identify such changes, which might be used as predictive markers of risk to develop liver cancer and as molecular targets for novel pharmacological strategies to treat these tumors. In particular, the main objective of this project is to study the role of the post-translational modifications (PTMs) of proteins, NEDDylation in particular, in the development and progression of CCA.

COVID19aren ondoriozko osasun-egoeren ondorioz, Tesiaren defentsa online egingo da. Esteka honen bidez jarrai daiteke: